Syncona Limited - Director Declaration

Syncona

06/03/2024 17:22

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF8912Fa&default-theme=true

RNS Number : 8912F  Syncona Limited  06 March 2024

Syncona Limited (the "Company")

Director Declaration

 

6 March 2024

In accordance with the requirements of the Listing Rule 9.6.14R, the Company
advises the following change to directorships in other publicly quoted
companies held by the following member of the Board:

Dr Julie Cherrington was appointed to Elevation Oncology, Inc. (Nasdaq: ELEV)
on 4 March 2024.

Enquiries

Syncona Ltd

Alasdair Moodie

Tel: +44 (0) 20 3981 7940

 

Citco Fund Services (Guernsey) Limited

Company Secretary

Tel: +44 (0) 1481 758200

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading life
science businesses, across development stage, modality and therapeutic areas,
for the benefit of all our stakeholders. We focus on developing treatments for
patients by working in close partnership with world-class academic founders
and management teams. Our balance sheet underpins our strategy enabling us to
take a long-term view as we look to improve the lives of patients with no or
poor treatment options, build sustainable life science companies and deliver
strong risk-adjusted returns to shareholders.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNDQLFBZXLLBBB